鼻中隔鼻甲成形术后辅助舌下免疫治疗的疗效
这项非随机对照研究在台湾一家三级医院纳入96例尘螨过敏性鼻炎合并鼻中隔偏曲和下鼻甲肥大的患者,均行鼻中隔鼻甲成形术,术后分为单纯手术组44例和手术联合舌下免疫治疗组52例。术后第3、6个月联合组鼻结膜炎控制评估测试总分优于单纯手术组(28.6±1.56 vs 24.5±3.66,p<0.001;27.1±2.87 vs 19.9±5.56,p<0.001)。作者认为舌下免疫治疗可作为鼻中隔鼻甲成形术后的辅助治疗。
要点
- 术后第3个月联合组RCAT总分28.6±1.56 vs 单纯手术组24.5±3.66,p<0.001。
- 术后第6个月联合组RCAT总分27.1±2.87 vs 单纯手术组19.9±5.56,p<0.001。
- 术后第3、6个月联合组所有RCAT子类控制均显著优于单纯手术组。
核心结论
- 舌下免疫治疗可能作为尘螨过敏性鼻炎患者鼻中隔鼻甲成形术后的理想辅助治疗。
研究设计与样本
- 非随机对照研究,在台湾一家三级医院招募尘螨过敏性鼻炎合并鼻中隔偏曲和下鼻甲肥大的患者,均行鼻中隔鼻甲成形术。
- 共纳入96例患者,分为单纯手术组44例和手术联合舌下免疫治疗组52例。
- 分析人口学数据和鼻结膜炎控制评估测试(RCAT)结果。
主要发现
- 术前及术后1个月两组各项变量均无显著差异。
- 术后第3个月联合组RCAT总分28.6±1.56 vs 单纯手术组24.5±3.66,p<0.001。
- 术后第6个月联合组RCAT总分27.1±2.87 vs 单纯手术组19.9±5.56,p<0.001。
- 术后第3、6个月联合组所有RCAT子类控制均显著优于单纯手术组。
关键数值与推荐
- RCAT总分术后第3个月联合组28.6±1.56 vs 单纯手术组24.5±3.66,p<0.001。
- RCAT总分术后第6个月联合组27.1±2.87 vs 单纯手术组19.9±5.56,p<0.001。
临床怎么用
- 作者认为舌下免疫治疗可能作为尘螨过敏性鼻炎患者鼻中隔鼻甲成形术后的理想辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of adjuvant sublingual immunotherapy (SLIT) in correcting structural problems in patients with allergic rhinitis (AR) caused by mite who have undergone septomeatoplasty (SMP) has not been studied. METHODS: This non-randomized controlled study recruited patients with AR (caused by mite) and concurrent septal deviation and inferior turbinate hypertrophy, at a tertiary hospital in Taiwan. SMP was performed on all patients as a surgical intervention. The patients were then divided into two groups: the control group, which underwent surgery only, and the experimental group, which received SLIT as an adjuvant treatment. Demographic data and rhinitis control assessment test (RCAT) results were analyzed. RESULTS: A total of 96 patients were enrolled in the study (SMP + SLIT group, n = 52; SMP only group, n = 44). No significant differences were observed in any of the variables between the two groups before and one month after surgery. However, during evaluations at the third and sixth month, the SMP + SLIT group showed significant improvement in the total RCAT scores compared to the SMP only group (28.6 ± 1.56 vs. 24.5 ± 3.66, p < 0.001; 27.1 ± 2.87 vs. 19.9 ± 5.56, p < 0.001). In addition, significantly better control of all RCAT sub-categories was observed in the SMP + SLIT group at the third and sixth month evaluations. CONCLUSIONS: SLIT may serve as an ideal adjuvant therapy after SMP in patients with AR. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:3073-3079, 2024.
引用
- Hsieh BH, Kuo YC, Yong SB, et al. Efficacy of Adjuvant Sublingual Immunotherapy After Septomeatoplasty. Laryngoscope. 2024. PMID: 38372411. doi:10.1002/lary.31347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。